C.R. Bard, Inc. (NYSE:BCR) declared a quarterly dividend on Wednesday, October 11th, RTT News reports. Investors of record on Friday, December 8th will be given a dividend of 0.26 per share by the medical instruments supplier on Friday, December 29th. This represents a $1.04 dividend on an annualized basis and a yield of 0.32%.
C.R. Bard has increased its dividend payment by an average of 6.8% annually over the last three years and has raised its dividend every year for the last 45 years. C.R. Bard has a dividend payout ratio of 8.8% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect C.R. Bard to earn $12.93 per share next year, which means the company should continue to be able to cover its $1.04 annual dividend with an expected future payout ratio of 8.0%.
C.R. Bard (NYSE BCR) remained flat at $321.57 on Thursday. 16,996 shares of the stock were exchanged. C.R. Bard has a 1-year low of $203.63 and a 1-year high of $324.58. The stock has a market capitalization of $23.37 billion, a PE ratio of 42.22 and a beta of 0.58. The company has a 50-day moving average of $320.14 and a 200-day moving average of $306.99.
C.R. Bard (NYSE:BCR) last issued its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, topping the consensus estimate of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The business had revenue of $979.70 million during the quarter, compared to the consensus estimate of $976.53 million. During the same quarter last year, the company earned $2.54 EPS. The firm’s revenue was up 5.2% compared to the same quarter last year. On average, equities research analysts anticipate that C.R. Bard will post $11.81 EPS for the current fiscal year.
Several brokerages have commented on BCR. Jefferies Group LLC restated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research note on Thursday, September 14th. BidaskClub downgraded C.R. Bard from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Zacks Investment Research downgraded C.R. Bard from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, BMO Capital Markets restated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research note on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $292.00.
In other news, insider John P. Groetelaars sold 23,687 shares of C.R. Bard stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the sale, the insider now owns 31,445 shares in the company, valued at approximately $10,022,464.85. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Timothy P. Collins sold 8,388 shares of C.R. Bard stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $322.00, for a total value of $2,700,936.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 62,327 shares of company stock valued at $19,931,334. Corporate insiders own 0.80% of the company’s stock.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.